Composition for preventing or alleviating skin aging, comprising lacticaseibacillus paracasei subsp. paracasei ABF21013

Abstract

The present invention relates to a composition for preventing or alleviating skin aging, the composition comprising Lacticaseibacillus paracasei subsp. paracasei ABF21013. The composition according to the present invention exhibits excellent effects in improving skin wrinkles and skin elasticity and exhibiting skin moisturizing ability, and thus has the advantage of being able to effectively prevent or alleviate skin aging.

Description

Composition for preventing or improving skin aging comprising Lacticase bacillus paracasei subspecies paracasei ABF21013

[0001] The present invention relates to a composition for preventing or improving skin aging comprising Lacticaseibacillus paracaseis subsp. paracasei ABF21013.

[0002] The human intestines are home to a diverse range of microbiota, and their balance influences physical health. For example, if the balance of the intestinal microbiota is disrupted and the population of specific pathogens increases, various inflammatory diseases may occur, including inflammatory bowel disease (IBD), atherosclerosis, rheumatoid arthritis, sepsis, allergies, and atopic dermatitis. Probiotics, including lactic acid bacteria, help maintain homeostasis by inhibiting the growth of harmful intestinal bacteria and controlling systemic inflammatory responses through interactions with intestinal epithelial cells and resident macrophages.

[0003] For this reason, individually recognized probiotic ingredients touted for various functionalities (skin health, menopausal relief, body fat reduction, etc.) have recently been obtaining functional certification from the Ministry of Food and Drug Safety. According to the Korea Health Functional Food Association, the domestic inner beauty market grew tenfold in eight years, surpassing 500 billion won (2011) to 500 billion won (2019). Furthermore, the market is growing significantly every year, to the extent that Shinhan Investment & Securities predicted the market size to reach 1.1942 trillion won in 2022. However, there are almost no products utilizing domestically sourced materials among domestic inner beauty ingredients, and in particular, there are very few cases where lactic acid bacteria have received functional certification, with the exception of CJLP133 and HY7714. Therefore, we expect to lead the domestic and international inner beauty markets by securing diverse functional data and obtaining functional certifications utilizing our lactic acid bacteria strains (source materials).

[0004] The present invention aims to provide the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain (accession number: KCTC 16093BP).

[0005] In addition, the present invention aims to provide the efficacy of improving or preventing skin aging with a composition comprising the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain.

[0006] The present invention provides the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain (accession number: KCTC 16093BP).

[0007] The present invention provides a food composition for preventing or improving photoaging comprising the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain (accession number: KCTC 16093BP).

[0008] In the food composition according to the present invention, the strain may comprise one or more combinations selected from, for example, the live cells of the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain, the lysate thereof, the culture solution thereof, the culture solution thereof, the concentrate thereof, the dried product thereof, the extract thereof, the extract thereof, and the dead cells thereof.

[0009] In the food composition according to the present invention, the photoaging is preferably induced by ultraviolet irradiation.

[0010] The present invention provides a food composition for improving wrinkles or enhancing skin elasticity comprising the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain (accession number: KCTC 16093BP).

[0011] The present invention provides a moisturizing food composition comprising the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain (accession number: KCTC 16093BP).

[0012] The present invention provides a cosmetic composition for preventing or improving photoaging comprising the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain (accession number: KCTC 16093BP).

[0013] In the cosmetic composition according to the present invention, the strain may comprise, for example, a combination of one or more selected from the live cells of the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain, the lysate thereof, the culture solution thereof, the culture solution thereof, the concentrate thereof, the dried product thereof, the extract thereof, the extract thereof, and the dead cells thereof.

[0014] In the cosmetic composition according to the present invention, the photoaging is preferably induced by ultraviolet irradiation.

[0015] The present invention provides a cosmetic composition for improving wrinkles or enhancing skin elasticity comprising the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain (accession number: KCTC 16093BP).

[0016] The present invention provides a moisturizing cosmetic composition comprising the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain (accession number: KCTC 16093BP).

[0017] The composition according to the present invention has the advantage of effectively preventing or improving skin aging by exhibiting excellent skin wrinkle and skin elasticity improvement and skin moisturizing ability.

[0018] Figure 1 is a schematic diagram showing the schedule for ultraviolet irradiation and surface measurement.

[0019] Figure 2 shows the results of confirming changes in skin thickness following the administration of the Lacticase Bacillus paracasei subspecies paracasei (Lc. paracasei) ABF21013 strain.

[0020] Figure 3 shows the results of confirming changes in skin moisture content and transepidermal water loss following the administration of the Lacticase Bacillus paracasei subspecies paracasei (Lc. paracasei) ABF21013 strain.

[0021] Figure 4 shows the results of confirming changes in skin elasticity following the administration of the Lacticase Bacillus paracasei subspecies paracasei (Lc. paracasei) ABF21013 strain.

[0022] Figure 5 shows the results of confirming the change in the degree of skin wrinkle formation following the administration of the Lacticase Bacillus paracasei subspecies paracasei (Lc. paracasei) ABF21013 strain in a replica.

[0023] Figure 6 shows the results of evaluating the efficacy of skin wrinkle improvement following the administration of the Lacticase Bacillus paracasei subspecies paracasei (Lc. paracasei) ABF21013 strain.

[0024] Figure 7 shows the results of confirming the change in expression levels of wrinkle-related markers following the administration of the Lacticase Bacillus paracasei subspecies paracasei (Lc. paracasei) ABF21013 strain.

[0025] Figure 8 shows the results of confirming changes in the expression levels of moisturizing-related markers (filaggrin, hyaluronan synthase) following the administration of the Lacticase Bacillus paracasei subspecies paracasei (Lc. paracasei) ABF21013 strain.

[0026] Figure 9 shows the results of confirming the change in hyaluronic acid expression levels following the administration of the Lacticase Bacillus paracasei subspecies paracasei (Lc. paracasei) ABF21013 strain.

[0027] In the following, redundant content has been omitted to prevent clutter. In other words, the content of the invention is not limited solely to the following, and should be interpreted in accordance with the overall context of the invention.

[0028]

[0029] In one embodiment of the present invention, when the strain Lacticase Bacillus paracasei subspecies paracasei (Lc. paracasei) ABF21013 (hereinafter referred to as ABF21013 lactic acid bacteria) according to the present invention was repeatedly orally administered to mice that had induced photoaging by ultraviolet rays for 12 weeks, it was confirmed that there were statistically significant differences in skin elasticity, moisture content, moisture loss, skin wrinkles, histopathological examination, MMPs, HA, mRNA levels of skin health-related genes, and protein levels compared to the ultraviolet irradiation group (ultraviolet only). Significant changes resulting from the intake of the strain according to the present invention occurred starting from the 4th week.

[0030] Matrix metalloproteinases (MMPs) are zinc-containing endopeptidases with broad substrate specificity and can be classified into five major subgroups based on their structure and substrate specificity. Changes in the extracellular matrix (ECM) caused by MMPs induce skin wrinkles, which are a characteristic of premature skin aging. Among these, MMP-1 and MMP-13 belong to a subgroup of collagenases and are major enzymes responsible for the degradation of type I collagen. These enzymes can degrade various components of extracellular matrix (ECM) proteins, and the degradation of pro-collagen is accelerated by collagenase increased by ultraviolet radiation, resulting in a lower pro-collagen content in the dermis. In one embodiment of the present invention, it was confirmed that ultraviolet irradiation increased the expression of MMP-1 and MMP-13 and inhibited the expression of type I pro-collagen.

[0031] In addition, Col1a1, a collagen synthesis gene, is involved in the production of a portion of Type I collagen. Collagen is known as a group of proteins that strengthens and supports many tissues of the body, such as cartilage, bone, tendons, skin, and the whites of the eyes. In one embodiment of the present invention, Col1a1 gene expression was significantly reduced by UV treatment, and it was confirmed that this suppression of expression was increased (recovered) by the intake of the ABF21013 HD group.

[0032] In addition, HAS (Hyaluronan synthase) is a membrane-bound enzyme that uses UDP-α-N-acetyl-D-glucosamine and UDP-α-D-glucuronate as substrates to generate the glycosaminoglycan hyaluronan at the cell surface and push it through the membrane into the extracellular space. It is generally known that UV irradiation inhibits the expression of HAS in skin keratinocytes, such as by suppressing the expression of hyaluronan synthase, which causes a decrease in hyaluronic acid (HA) in the dermis of mice. In other words, it is generally known that UV irradiation inhibits the expression of HAS genes and consequently reduces the HA content. In one embodiment of the present invention, the mRNA expression of HAS1 and HAS2 and the HA protein expression in the dermis were significantly reduced by UV irradiation, and it was confirmed that the HAS genes and HA proteins were restored to a level similar to that of the negative control group (untreated group) in the test group that consumed ABF21013 lactic acid bacteria. In addition, it was confirmed that the content of HA increased in the dorsal skin tissue (epidermis + dermis) of mice irradiated with ultraviolet rays, and this increase was consistent with changes in HAS1 and HAS2 mRNA levels that increased due to ultraviolet irradiation.

[0033] In addition, Filaggrin is a cationic protein rich in histidine, produced by the degradation of profilaggrin; it aggregates keratin filaments within keratinocytes and, upon reaching the upper layer of the stratum corneum, is degraded into amino acids to act as a natural moisturizing factor. In one embodiment of the present invention, Filaggrin mRNA expression is at a high concentration (1 x 10⁻⁶ 10 By consuming ABF21013 (CFU / day), expression levels were restored to normal or further increased.

[0034] Based on the above results, the inventors determined that consuming ABF21013 lactic acid bacteria can effectively control the decrease in elasticity, decrease in moisture content, increase in transepidermal water loss, and increase in skin wrinkles induced by ultraviolet rays.

[0035] Accordingly, the inventors have confirmed that oral intake of the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain according to the present invention is effective in improving skin damage in experimental animals induced by photoaging from ultraviolet rays, and intend to provide the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain (Deposit No.: KCTC 16093BP, Deposit Date: October 16, 2024; Korea Research Institute of Biotechnology and Bioengineering Center (KCTC, 181 Ipsin-gil, Jeongeup-si, Jeollabuk-do)) and a composition containing the same for use in improving photoaging and skin wrinkles, and for promoting skin elasticity and moisturizing the skin.

[0036] At this time, the above photoaging is preferably induced by ultraviolet irradiation.

[0037] At this time, the strain may comprise one or more combinations selected from, for example, the live cells of the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain, the lysate thereof, the culture solution thereof, the culture solution thereof, the concentrate thereof, the dried product thereof, the extract thereof, the extract thereof, and the dead cells thereof.

[0038] The term "crushed material of the strain" as used in the present invention refers to crushed material of a strain, and designates strains that have been crushed by applying physical force or chemical treatment.

[0039] The term 'culture solution' used in the present invention refers to a culture solution in which a strain is cultured, and a conventional lactic acid bacteria medium may be used for culturing the strain.

[0040] The term "culture thereof" as used in the present invention refers to a powder produced by drying or volatilizing a culture solution in which a strain has been cultured.

[0041] The term "concentrate thereof" as used in the present invention refers to a concentrated strain culture solution described above.

[0042] The term "dried product thereof" as used in the present invention refers to a powder obtained by drying the strain culture solution or strain concentrate described above.

[0043] The term 'extract of this' used in the present invention refers to an extract obtained by adding an extraction solvent to a strain.

[0044] The term "extract of this" as used in the present invention refers to a powder prepared by drying or volatilizing the extraction solvent from an extract obtained by adding an extraction solvent to a strain.

[0045] The term 'dead bacterial body' used in the present invention refers to a bacterial strain that has been killed, and the killing of the bacterial strain means killing it by applying heat, applying pressure, grinding with beads, or by enzymatic and chemical treatment, and refers to a so-called 'dead bacterial pulverized material' in which the bacterial body is crushed by the killing treatment.

[0046]

[0047] As one preferred example for achieving the above-mentioned purpose, the present invention provides a food composition for preventing or improving photoaging comprising the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain (accession number: KCTC 16093BP).

[0048] As another preferred example for achieving the above-mentioned purpose, the present invention provides a food composition for improving wrinkles or enhancing skin elasticity comprising the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain (accession number: KCTC 16093BP).

[0049] As another preferred example for achieving the above-mentioned purpose, the present invention provides a moisturizing food composition comprising the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain (accession number: KCTC 16093BP).

[0050] The term "improvement" according to the present invention refers to any act in which skin aging is improved or beneficially altered by the administration of a composition according to the present invention.

[0051] In the food composition according to the present invention, the strain according to the present invention is preferably included in an amount of 0.00001 to 50 weight% relative to the food composition. If the amount is less than 0.00001 weight%, the effect is negligible, and if the amount exceeds 50 weight%, the increase in effect relative to the amount used is insignificant and therefore uneconomical.

[0052] The food composition according to the present invention may be, for example, a probiotic, synbiotic, or postbiotic composition. In addition, it may be manufactured in any one form selected from noodles, chewing gum, dairy products, ice cream, meat, grains, caffeinated beverages, general beverages, chocolate, bread, snacks, confectionery, candy, pizza, jelly, sauce, alcoholic beverages, alcohol, vitamin complexes, and other health supplements, but is not necessarily limited thereto.

[0053] When the food composition according to the present invention is used as a food additive, it may be added as is or used together with other foods or food ingredients, and may be used appropriately according to conventional methods.

[0054] The term "health functional food" above refers to a food manufactured and processed using raw materials or ingredients that have functional properties useful to the human body pursuant to Article 6727 of the Health Functional Foods Act, and the term "functional properties" means consuming for the purpose of obtaining useful effects for health purposes, such as regulating nutrients for the structure and function of the human body or physiological actions.

[0055] The health functional food (supplement) according to the present invention may include additional ingredients that can improve the smell, taste, and appearance. For example, it may include biotin, folate, pantothenic acid, vitamins A, C, D, E, B1, B2, B6, B12, niacin, etc. In addition, it may include minerals such as chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), zinc (Zn), iron (Fe), and calcium (Ca). In addition, it may include amino acids such as cysteine, valine, lysine, and tryptophan. In addition, food additives such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dihydroacetate, etc.), coloring agents (tar dyes, etc.), colorants (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite), disinfectants (bleaching powder and high-grade bleaching powder, sodium hypochlorite, etc.), leavening agents (alum, potassium hydrogen tartrate, etc.), reinforcing agents, emulsifiers, thickeners (sizing agents), coating agents, antioxidants [butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), etc.], seasonings (MSG, monosodium glutamate, etc.), sweeteners (dulcin, cyclamate, saccharin, sodium, etc.), flavorings (vanillin, lactones, etc.), gum bases, antifoaming agents, solvents, and improvers may be added. The above additives may be selected according to the type of food and used in appropriate amounts.

[0056] In the health functional food according to the present invention, the content of the strain according to the present invention is not particularly limited and can be varied depending on the condition of the subject to administration, the specific type of disease, the degree of progression, etc. If necessary, it may also be included in the total content of the food.

[0057]

[0058] As another preferred example for achieving the above-mentioned purpose, the present invention provides a cosmetic composition for preventing or improving photoaging comprising the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain (accession number: KCTC 16093BP).

[0059] As another preferred example for achieving the above-mentioned purpose, the present invention provides a cosmetic composition for improving wrinkles or enhancing skin elasticity comprising the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain (accession number: KCTC 16093BP).

[0060] As another preferred example for achieving the above-mentioned purpose, the present invention provides a moisturizing cosmetic composition comprising the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain (accession number: KCTC 16093BP).

[0061] In the present invention, the strain is preferably contained in an amount of 0.00001 to 30.0% by weight based on the total weight of the cosmetic composition. More preferably, it is contained in an amount of 0.01 to 10% by weight based on the total weight of the cosmetic composition. If the content of the strain is less than 0.00001% by weight, no skin aging improvement effect is observed, and if it exceeds 30.0% by weight, no significant increase in effect is observed with increasing content.

[0062] Meanwhile, the components included in the cosmetic composition of the present invention may include, in addition to the strain of the present invention as active ingredients, components commonly used in cosmetic compositions, such as, for example, antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances, and carriers.

[0063] The cosmetic composition of the present invention may be prepared in any formulation conventionally manufactured in the art, for example, as a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, pack, massage cream, and spray, but is not limited thereto. More specifically, it may be prepared in the form of a softening lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray, or a powder.

[0064] In the case where the formulation of the cosmetic composition of the present invention is a paste, cream, or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide may be used as a carrier component.

[0065] When the formulation of the cosmetic composition of the present invention is a solution or an emulsion, a solvent, a solubilizing agent, or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan.

[0066] When the formulation of the cosmetic composition of the present invention is a suspension, a liquid diluent such as water, ethanol, or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracanthenic acid may be used as a carrier component.

[0067] When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, it may additionally include a propellant such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether.

[0068] In the case where the formulation of the cosmetic composition of the present invention is a cleansing product containing a surfactant, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester, etc. may be used as a carrier component.

[0069] When the cosmetic composition of the present invention is a soap, a cleansing formulation containing a surfactant, or a cleansing formulation not containing a surfactant, it may be wiped off, peeled off, or washed off with water after application to the skin. As specific examples, the soap is a liquid soap, powder soap, solid soap, and oil soap; the cleansing formulation containing a surfactant is a cleansing foam, cleansing water, cleansing towel, and cleansing pack; and the cleansing formulation not containing a surfactant is a cleansing cream, cleansing lotion, cleansing water, and cleansing gel, but is not limited thereto.

[0070]

[0071] Hereinafter, the contents according to the present invention are to be explained in more detail through the following examples or experimental examples. However, the scope of rights according to the present invention is not limited only to the following examples of examples or experiments, but also includes variations of equivalent technical concepts.

[0072]

[0073] Experimental method

[0074] 1. Composition of the test group

[0075] The animal groups were separated as follows:

[0076] First, body weight measurements were performed, and the required number of animals close to the average were selected. The measured animal weights were ranked, and the animals were randomly distributed as per the experimental group composition to ensure that the average values ​​of each group were evenly distributed. The specific experimental group composition is shown in Table 1 below.

[0077] Experimental Group | Gender | Number of Animals | Animal Number | Dose (CFU / day) | Administered Substance Untreated | F8 | 1-8-PBS | UV only | F8 | 9-16-PBS | UV+ | AB | F2 | 10 | 13 | LDF | 8 | 17-24 | 1x10 9 Lc. paracaseiABF21013UV+ ABF21013HDF825-321x10 10 Lc. paracaseiABF21013

[0078]

[0079] 2. Administration

[0080] The Lacticase-Bacillus paracasei subspecies paracasei (Lc. paracasei) ABF21013 strain is at a low concentration (LD; 1 x 10⁻¹⁰) based on the daily intake of lactic acid bacteria. 9 ) and high concentration (HD; 1x10 10 ) was mixed with 100 µl of physiological saline and administered orally. The above strain was administered by fixing the animal's cervix and using a 1 ml syringe once a day, five times a week, for a total of 60 times over 12 weeks, reflecting the planned clinical route.

[0081]

[0082] 3. Induction of photoaging by ultraviolet irradiation

[0083] To induce photoaging, one hairless mouse was placed in a polycarbonate rearing box (W 170 × L 235 × H 125 mm) and a UV irradiation device was installed.

[0084] UVB was selected as the ultraviolet light, and irradiation was performed at an intensity that induces the minimal erythema dose (MED). Specifically, irradiation was performed three times at 25 mJ / cm² (1 MED) during the first week, three times at 50 mJ / cm² (2 MED) during the second week, three times at 75 mJ / cm² (3 MED) during the third week, and three times per week at 100 mJ / cm² (4 MED) during weeks 4 through 12 (Fig. 1). Fig. 1 is a schematic diagram showing the schedule for ultraviolet irradiation and surface measurement.

[0085]

[0086] 4. Measurement of skin health indicators

[0087] Skin elasticity, skin moisture content, transepidermal water loss, and replica production among skin health indicators were measured under isoflurane inhalation anesthesia before administration of the test substance (week 0) and at weeks 4, 8, and 12 after administration.

[0088]

[0089] A. Skin elasticity

[0090] Skin elasticity was measured using a Cutometer. Specifically, the Cutometer probe was placed in close contact with the mouse skin at a right angle, and measurements were taken. During the measurement, the same pressure was applied to the skin at 450 mbw, and measurements were repeated three times for 2 seconds each. In this test, the R2 (Ua / Uf) mode, which utilizes the skin's ability to return to its original state after deformation, was used. The R2 mode is a primary parameter for evaluating skin elasticity and wrinkles, and is associated with the skin's elastic fibers; a value closer to 1 was evaluated as indicating more elastic skin.

[0091]

[0092] B. Skin moisture content

[0093] Skin moisture content was measured using a Corneometer. Specifically, the Corneometer utilized the principle that the dielectric constant (ε, dielectric conductivity) of the skin increases as the moisture content increases. After turning on the Corneometer, the measurement value appears on the screen when the probe is lightly pressed on the measurement site. The measurement area was measured three times.

[0094]

[0095] C. Transepidermal Water Loss

[0096] Transepidermal water loss was measured using a Tewameter. A Tewameter is a device that measures water loss through the skin. Within the 10 mm thick microenvironment surrounding the skin, a water vapor gradient exists between the skin surface and the surrounding space. That is, assuming that water diffuses from the skin surface into the air, the amount of water radiating from the skin was calculated by measuring the vapor pressure at two points at a certain height above the skin. After turning on the power, the probe was placed on the measurement site, and the measurement button was pressed to measure transepidermal water loss for 30 minutes.

[0097]

[0098] D. Replica Production and Analysis

[0099] The replica was measured using Visioline. The Visioline VL650 is a device capable of measuring the depth and length of wrinkles. It is designed to allow a skin replica to be inserted into a standard cartridge that is engineered to allow a special light source to pass through. Light is applied perpendicularly to the skin wrinkles (especially deep wrinkles) using oblique Lightning (incident angle approximately 35 degrees) through the skin replica, which is created using an optical profilometer method. After converting the shadow intensity images generated according to the thickness of the skin replica into files using a CCD camera, the depth and length of the wrinkles were measured using the Skin Visioline VL650 software, an image analysis system. After turning on the power, the replica was placed in the sample slot, and the capture button in the program was pressed to save the image.

[0100]

[0101] 5. Autopsy

[0102] Mice were anesthetized by intraperitoneal administration of 1 ml / kg of a mixture of 1 mg / kg of Zolletil and Rumpun at a ratio of 4:1 (v / v) 12 weeks after the experiment, on the day of necropsy. Skin tissues were collected from the anesthetized mice and subjected to histopathological analysis, ELISA, WB (western blotting), and RT-qPCR analysis.

[0103]

[0104] 6. Histomorphometric analysis

[0105] After sacrificing the experimental animals, dorsal skin tissue was excised, cut into longitudinal sections, and rapidly frozen in liquid nitrogen. For H&E (Hematoxylin and esosin) staining and immunohistochemistry analysis, the skin tissue was fixed in a 10% neutral buffered formalin solution for 24 hours. Subsequently, the fixed skin tissue was prepared into paraffin blocks, and slides were prepared by trimming and cutting to 3-4 µm using a microtome (RM2255, Leica Biosystems, Germany). The thickness of the epidermis and stratum corneum was analyzed using H&E staining on the prepared slides, and the expression levels of MMP-1 and MMP-13 in the skin tissue were analyzed using anti-MMP-1 and anti-MMP13 antibodies.

[0106]

[0107] 7. ELISA, Western blotting and RT-qPCR

[0108] A. ELISA

[0109] Mouse dorsal skin tissue, rapidly frozen with liquid nitrogen, was thawed overnight at 4°C using RIPA buffer supplemented with a proteinase inhibitor (25 μL RIPA buffer per 1 mg of tissue; Atto, Japan), and the extract supernatant was obtained by centrifugation (13,000 rpm, 10 min). The experiment to measure HA content in the tissue was performed using Quantikine TM The ELISA Hyaluronan Immunoassay (#DHYAL0, R&D Systems, MN, USA) was used and performed according to the manufacturer's instructions. The standardization graph for HA was prepared using the hyaluronan standard included in the kit.

[0110] The total protein content of mouse skin tissue is based on Pierce's comparison with the supernatant of tissue extracts obtained from mice. TM Quantification was performed using the BCA protein Assay kit (Thermo Scientific, MA, USA). A standardization graph for total protein was constructed using BSA (MP Biomedicals, #160069, Seoul, Korea). The amount of HA derived from the kit was divided by the total protein amount of the tissue to determine the HA content in the mouse skin tissue.

[0111]

[0112] B. Western Blot

[0113] 25 µl of RIPA butter (with protease and phosphate inhibitor cocktail) was added per 1 mg of mouse dorsal skin tissue, and overnight rotation was performed at 4°C. The supernatant of the extract was obtained by centrifugation (3,000 rpm, 5 min), and 150 µl of 2X reducing buffer was added to 150 µl of the supernatant, followed by heat treatment at 100°C for 5 min. 20 µl of the sample was separated using a 10–12% SDS-PAGE system (25 mM Tris, 250 mM glycine, 0.1% SDS) and transferred to a polyvinylidene fluoride (PVDF) membrane using a power supply (100V, 2 hours).

[0114] The membrane was blocked with TBS-T buffer (20 mM Tris-HCl, 150 mM NaCl, 0.05% Tween-20, 5% skim milk) for 1 hour at room temperature (RT). The primary antibody diluted in TBS-T buffer and the HRP-conjugated secondary antibody were sequentially applied to the membrane. Target proteins were visualized using an enhanced chemiluminescence (ECL) reagent (EZ-western Lumi Pico, DG-WP500, DoGenBio, Seoul, Korea) and a chemiluminescence imaging device (Chemidoc, iBright 750, Invitrogen, CA, USA).

[0115] In this experiment, anti-MMP1 (AB137332, Abcam, MA, USA), anti-MMP13 (AB39012, Abcam), anti-c-Jun (AB31419, Abcam), anti-c-Fos (AB190289, Abcam), anti-procollagen (ABT257, SigmaAldrich, MO, USA), anti-β-actin (sc-47778, Santa Cruz Biotechnology, TX, USA) and mouse anti-rabbit IgG-HRP (sc-2357, Santa Cruz) antibodies were used.

[0116]

[0117] C. RT-qPCR

[0118] To measure mRNA expression levels, 50 µl of RNA-Bee reagent (CS-104B, AMSBIO, MA, USA) was added per 1 mg of mouse skin tissue, and total RNA was isolated by overnight rotation at 4°C. cDNA was synthesized using the isolated total RNA and an iScript cDNA synthesis kit (Bio-Rad, CA, USA). Genetic mutations in mouse skin tissue were quantified using real-time PCR (AriaMx Real-Time PCR system, IG8830A-1FIL, Agilent Technologies, CA, USA).

[0119]

[0120] 8. Statistical Analysis

[0121] The measurement results were calculated as mean and standard deviation and expressed as mean ± SD. Statistical analysis of the experimental results was performed using Student's t-test, 1-way ANOVA (Tukey's Multiple Comparison Test), and 2-way ANOVA with Prism Ver 5.01 (GraphPad Software, Inc, La Jolla, CA, USA). Significance was tested for comparisons between the normal group and the UV-treated group, and between the UV-treated group and the lactic acid bacteria intake group, at the levels of *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001 (comparison between the untreated group and the UV-only group) and #p<0.05, ##p<0.01, ###p<0.001, and ####p<0.0001 (comparison between the UV-only group and the lactic acid bacteria intake group), respectively.

[0122]

[0123] [Example 1: Preparation of Test Substance]

[0124] 1. Creation of a lactic acid bacteria growth curve

[0125] A single colony was taken from a plate containing a strain derived from Makgeolli, inoculated into 10 ml of MRS broth, and cultured overnight. 1 ml of the overnight culture was diluted with MRS liquid medium to an OD value of 1.0 measured at 600 nm, and inoculated into a new MRS liquid medium at 1 / 100 volume and cultured for 10 to 16 hours.

[0126] During culture, 1 ml was collected at 2-hour intervals to measure the OD600 value, and another 1 ml was serially diluted 1 / 10 and plated onto an MRS agar plate to form colonies. On the next day, the colonies formed on the plate were counted to construct an OD growth graph and a CFU graph according to culture time, and an equation for exponential growth was constructed using the OD vs CFU graph.

[0127] Some of the overnight cultured lactic acid bacteria (OD600=1.0) were stock-stored at -80℃ after adding 25% glycerol.

[0128] As a result of sequencing the strain, it was confirmed that the strain corresponds to 'Lacticaseibacillus paracasei subspecies paracasei (Lc.paracasei)', and it was named 'Lacticaseibacillus paracasei subspecies paracasei (Lc.paracasei) ABF21013', and the 16S rRNA sequencing result of the strain is shown in SEQ ID NO. 1.

[0129]

[0130] 2. Mass cultivation of lactic acid bacteria

[0131] 50 µl of stock lactic acid bacteria (Lc. paracasei ABF21013) was inoculated into 10 ml of MRS liquid medium and cultured in a 37°C incubator for 9 hours. The OD 600 value was measured using a spectrophotometer with 1 ml of the culture medium, and then diluted with MRS liquid medium to achieve an OD 600 value of 1.0. The diluted solution was inoculated into a new 10 ml of MRS liquid medium and pre-cultured in a 37°C incubator for 9 hours. The cultured lactic acid bacteria were then adjusted again to an OD 600 of 1.0, inoculated into 1 L of MRS liquid medium at a 1 / 100 volume, and main cultured in a 37°C incubator for 16 hours.

[0132] After the incubation was complete, the cells and culture medium were separated by centrifugation (8,000 RPM, 8 min). The separated cells were washed once with sterile PBS. The produced bacteria were 1 x 10⁶ 12 It was diluted to a concentration of CFU / mL and stored at 4℃. The stored lactic acid bacteria culture was fed to mice for 5 days, and expired lactic acid bacteria were discarded.

[0133] There was no significant difference in the total CFU / mL count from the day of sampling (day 0) to day 5.

[0134]

[0135] [Experimental Example 1: Evaluation of Skin Aging Improvement Efficacy]

[0136] 1. Observation of general symptoms

[0137] Observations of general symptoms in animal experiments revealed no animal deaths in any group due to UV irradiation or lactic acid bacteria intake, and no specific symptoms were observed. Measurements of body weight and feed intake showed no differences between groups. Accordingly, it is concluded that no adverse effects occurred from the intake of lactic acid bacteria.

[0138]

[0139] 2. Keratinization and changes in epidermal thickness

[0140] H&E staining results showed that the mouse skin tissue of the UV-only group exhibited significantly increased keratin formation compared to the Untreated group. On the other hand, the skin tissue of the experimental group that consumed the probiotic ABF21013 showed less keratin formation compared to the UV-only group.

[0141] Observing changes in epidermal thickness, UV treatment resulted in epidermal thickening; it was confirmed that the epidermal thickness of the UV-only group increased significantly compared to the untreated group. On the other hand, it was observed that the epidermal thickness of the experimental group that consumed probiotics was smaller than that of the UV-only group (left panel of Fig. 2).

[0142] As a result of measuring epidermal thickness, the average epidermal thickness of the UV-only group was 78.8±11.44 AU, which was 268% thicker than that of the Untreated group (29.4±3.77) (****p<0.0001). On the other hand, the average epidermal thickness of the groups that consumed the lactic acid bacteria ABF21013LD and ABF21013HD was 43.4±4.11 and 47.2±7.74, respectively, showing a significant decrease of approximately 44.87% and 40.13% compared to the UV-only group (####p<0.001) (Right panel of Fig. 2). Fig. 2 shows the results of confirming changes in skin thickness following the administration of the Lacticase Bacillus paracasei subspecies paracasei (Lc. paracasei) ABF21013 strain.

[0143] These results indicate that consuming the probiotic ABF21013 can effectively inhibit keratin formation caused by ultraviolet rays.

[0144]

[0145] 3. Changes in skin moisture content, transepidermal water loss, and skin elasticity

[0146] Significant decrease in skin moisture content due to UV rays occurred starting from week 8. Specifically, the change in skin moisture content in the UV-treated group was 52.7±9.5 at week 0, 39.7±7.3 at week 4, and 26.5±6.8 at week 12 (****p<0.0001), which was significantly reduced compared to Untreated.

[0147] The UV+ABF21013LD group showed 52.3±11.37, 50.9±9.76, and 57.4±5.24 (p<0.0001), while the UV+ABF21013HD group showed 50.4±8.6, 51.8±14.9 (p<0.05), and 54.5±9.3 (p<0.0001), demonstrating significantly higher skin moisture levels compared to the UV-only group after 4 weeks of probiotic intake.

[0148] In other words, a steady decrease in moisture was observed in the UV-only group compared to the normal group (untreated group) (****p<0.0001). On the other hand, significantly higher moisture content was measured in the experimental group that consumed ABF21013 compared to the UV-only group starting from week 4 (#p<0.05, ####p<0.0001) (Figure 3, left panel).

[0149] As a result of measuring transepidermal water loss, it was found that transepidermal water loss occurred steadily in the UV group starting from the 4th week of the test (**p<0.01 and ****p<0.0001), and a significant decrease was confirmed in the experimental group that consumed ABF21013 compared to the UV group (#p<0.05, ###p<0.001, ####p<0.0001) (Right panel of Fig. 3). Fig. 3 shows the results of confirming changes in skin moisture content and transepidermal water loss following the administration of the Lacticase Bacillus paracasei subspecies paracasei (Lc. paracasei) ABF21013 strain.

[0150] These results suggest that consuming ABF21013 lactic acid bacteria for more than 4 weeks exerts a skin moisturizing effect by inhibiting moisture loss caused by ultraviolet rays.

[0151] Meanwhile, the analysis of skin elasticity showed that the UV-only group exhibited a decrease in skin elasticity starting from week 4 compared to the normal group (*p<0.05) and showed a significant decreasing trend until week 12 (****p<0.0001). In addition, the experimental group that consumed ABF21013 showed a significant increase in skin elasticity compared to the UV-only group (##p<0.01, ####p<0.0001) (Fig. 4). Fig. 4 shows the results of confirming changes in skin elasticity following the administration of the Lacticase Bacillus paracasei subspecies paracasei (Lc. paracasei) ABF21013 strain.

[0152]

[0153] 4. Changes in skin wrinkle area, length, number, and depth

[0154] a. Skin wrinkle area

[0155] In the dorsal and replica photos of mice irradiated with UV light, wrinkle formation was observed starting from week 4, and deeper wrinkles formed at weeks 8 and 12. On the other hand, in the dorsal and replica photos of mice in two groups that consumed the probiotic ABF21013, wrinkle formation was reduced compared to the UV-only group.

[0156] That is, the total wrinkle area significantly increased over time in the UV-only group compared to the normal group (****p<0.0001). Compared to the UV-only group, the total wrinkle area of ​​the ABF21013LD intake group was found to significantly decrease starting from week 12 (####p<0.0001), and the ABF21013HD intake group showed a significant decrease starting from week 4 compared to the UV-only group (##p<0.01) (Fig. 5). Fig. 5 shows the results of confirming the change in the degree of skin wrinkle formation following the administration of the Lacticase Bacillus paracasei subspecies paracasei (Lc. paracasei) ABF21013 strain in Replica.

[0157] Meanwhile, regarding Wrinkle area (%), a significant decrease was observed in the ABF21013 treatment group starting from week 4 compared to the UV-only group (**p<0.01).

[0158] Specifically, the change in wrinkle area (%) was observed as 3.3±1.31% at week 0 for the UV-only group, 7.2±1.97% at week 4 after UV treatment, and 9.9±2.41% at week 12, confirming a gradual increase in wrinkle area (%). A significant difference was observed in this increase compared to untreated (****p<0.0001). The change in the UV+ABF21013LD group was 2.9±1.15% at week 0, 4.6±1.84% at week 4 (##p<0.01), and 5.5±2.04% at week 12 (####p<0.0001), and a significant difference occurred after week 4 compared to the UV-only group. The UV+ABF21013HD group showed 2.2±0.52%, 3.5±1.3%, and 3.3±0.83% at weeks 0–12, respectively, with a significant difference compared to the UV-only group after week 4 (####p<0.0001) (top left panel of Fig. 6).

[0159] From these results, it is determined that the ABF21013 lactic acid bacteria is highly effective in suppressing the wrinkle area (%) induced by ultraviolet rays when consumed for more than 4 weeks.

[0160]

[0161] B. Length of wrinkles

[0162] The total length (mm) increased in the UV-only group compared to the Untreated group due to UV treatment, with a significant difference occurring from week 4. When comparing the length of the wrinkles to the UV-only group, the UV+ABF21013LD group showed a significant decrease from week 12, and the UV+ABF21013HD group showed a significant decrease from week 4.

[0163] Specifically, the change in wrinkle length in the UV-only group from week 0 to week 12 was 38.1±15.39 mm, 76.4±19.22 mm, and 116.7±26.62 mm, showing a significant increase from week 4 compared to the untreated group (****p<0.0001), while the UV+ABF21013LD was 69.7±20.19 mm at week 12, showing a significant decrease compared to the UV-only group (####p<0.0001). UV+ABF21013HD values ​​were 28.5±10.69 mm, 36.9±11.27 mm, and 35.29±10.36 mm, showing a significant decrease after week 4 compared to the UV-only group (###p<0.001, ####p<0.0001) (Figure 6, upper right panel).

[0164] From these results, it is determined that consuming ABF21013LD lactic acid bacteria for 12 weeks or more and ABF21013HD lactic acid bacteria for 4 weeks or more effectively inhibits the occurrence of wrinkles (total wrinkle length) increased by ultraviolet rays.

[0165]

[0166] C. Number of wrinkles

[0167] The number of wrinkles in the UV-only group significantly increased from week 4 due to UV treatment compared to the untreated group. When comparing the number of wrinkles with the UV-only group, a significant decrease in the number of wrinkles was observed in the UV-+ABF21013LD group from week 12, and a significant decrease was observed in the UV-+ABF21013HD group from week 4.

[0168] Specifically, the change in the number of wrinkles in the UV-only group from week 0 to week 12 was calculated to be 111.3±23.37, 219±45.22, and 347.6±62.47, respectively, and a significant increase was confirmed at week 4 (****p<0.0001) and week 12 (****p<0.0001) compared to the untreated group.

[0169] The UV+ABF21013LD group showed values ​​of 127±21.37, 194±29.96, and 203.9±57.73, respectively, with a significant decrease observed at week 12 (p<0.0001) compared to the UV-only group. The UV+ABF21013HD group showed values ​​of 103.8±33.09, 132.3±24.81, and 139.9±37.53, with a significant decrease after week 4 compared to the UV-only group (p<0.001, p<0.0001) (bottom left panel of Fig. 6).

[0170] From these results, it is determined that consuming ABF21013LD lactic acid bacteria for 12 weeks or more and ABF21013HD lactic acid bacteria for 4 weeks or more effectively inhibits the occurrence of wrinkles (total number of wrinkles) that increase due to ultraviolet rays.

[0171]

[0172] D. Wrinkle depth

[0173] Wrinkle depth (㎛) significantly increased starting from week 4 of UV treatment compared to the untreated group. Compared to the UV-only group, the UV+ABF21013LD group showed a significant decrease in wrinkle depth starting from week 12, and the UV+ABF21013HD group showed a significant decrease starting from week 4.

[0174] Specifically, in the UV-only group, the wrinkle depth was 4885.6±2004.02 µm at week 0, 8930.1±1699.64 µm at week 4, and 12381.6±2180.27 µm at week 12, and significantly increased after week 4 (****p<0.0001).

[0175] The UV+ABF21013LD group showed 4955.8±1558.48 µm, 7697.2±1689.18 µm, and 8262.8±2010.47 µm at each week's measurements, and a significant difference from the UV only group occurred at week 12 (####p<0.0001).

[0176] Wrinkle depths of 3472.6±1067.5 µm, 5397.3±1492.07 µm, and 4035.8±1080.31 µm were measured for the UV+ABF21013HD group, showing a significant decrease starting from week 4 compared to the UV-only group (###p<0.001, ####p<0.0001) (bottom right panel of Fig. 6).

[0177] From these results, ABF21013LD (low dose, 1x10 9 When taking CFU / day), starting from week 12, ABF21013HD (high dose, 1x10 10 It is estimated that CFU / day inhibits the formation of wrinkles caused by ultraviolet rays starting from 4 weeks of intake.

[0178] Figure 6 shows the results of evaluating the efficacy of skin wrinkle improvement following the administration of the Lacticase Bacillus paracasei subspecies paracasei (Lc. paracasei) ABF21013 strain.

[0179]

[0180] 5. Changes in the expression levels of genes related to skin wrinkles and hydration

[0181] A. Expression levels of genes related to skin wrinkles

[0182] Compared to the untreated group, the UV-treated group induced an increase in the expression of MMP-1 mRNA by 4.02±0.48 times (**p<0.01) and MMP-13 mRNA mRNA by 4.13±0.04 times (***p<0.001).

[0183] In the UV+ABF21013LD intake group, MMP-1 expression was 2.36±0.08 times, which was significantly reduced compared to the UV-only group (#p<0.05), and MMP-13 expression was 2.10±0.14 times, which was significantly reduced compared to the UV-only group (###p<0.001).

[0184] In terms of regulating MMP-1 expression, compared to the untreated group, UV+ABF21013HD induced 1.51±0.01 times (**p<0.01) expression, showing a significant decrease in expression compared to the UV-only group, which induced 4.02±0.48 times. In the case of MMP-13, UV+ABF21013HD induced 2.12±0.16 times (###p<0.001) expression, showing a significant decrease in expression compared to the UV-only group, which induced 4.13±0.04 times.

[0185] Therefore, it is determined that consuming ABF21013 prevents and inhibits photoaging caused by increased UV-MMP expression.

[0186] Meanwhile, Col1a1 mRNA levels were expressed at 0.16±0.07 times the UV level due to UV treatment, which was significantly lower compared to the Untreated group (1.00±0.04) (**p<0.01). Compared to the UV-only group, UV+ABF21013LD showed no significant difference of 0.38±0.02 times, but UV+ABF21013HD showed a significant difference of 0.96±0.16 times compared to the UV-only group (##p<0.01) (Fig. 7). Fig. 7 shows the results of confirming the change in expression levels of wrinkle-related markers following the administration of the Lacticase Bacillus paracasei subspecies paracasei (Lc.paracasei) ABF21013 strain.

[0187] These results suggest that the intake of ABF21013 probiotics is effective in improving skin wrinkles by increasing the synthesis of Type I collagen.

[0188]

[0189] B. Expression levels of genes related to skin hydration

[0190] FLG(Filaggrin) mRNA levels increased by 1.32±0.03 times due to UV treatment, which was significantly higher compared to the Untreated group (1.00±0.01) (**p<0.01). Compared to the UV-only group, the UV+ABF21013HD group showed a significant increase (2.18±0.04 times, ####p<0.0001).

[0191] From these results, ABF21013 lactic acid bacteria is 1 x 10 10 It is believed that consuming more than CFU / day for 12 weeks or more produces a skin moisturizing effect by inducing the expression of natural moisturizing factors.

[0192] Meanwhile, HAS1 and HAS2 mRNA levels showed a significant decreasing trend due to UV treatment.

[0193] Specifically, HAS1 mRNA was 1.00±0.16 times in the Untreated group and 0.23±0.03 times in the UV-only group, showing a significant decrease compared to the Untreated group (*p<0.05). Among the lactic acid bacteria intake groups compared to the UV-only group, UV+ABF21013LD showed a tendency for increased expression of the HAS1 gene at 0.42±0.06 times and UV+ABF21013HD at 0.64±0.03 times.

[0194] HAS2 mRNA expression also decreased by 0.12±0.02 times in the UV-only group, showing a significant decrease compared to the Untreated group (1.00±0.06) (***p<0.001). Among the lactic acid bacteria intake experimental groups, the UV+ABF21013LD group showed an increasing trend compared to the UV-only group, with the UV+ABF21013HD group showing 0.18±0.00 times and the UV+ABF21013HD group showing 0.28±0.07 times (Fig. 8). Fig. 8 shows the results of confirming the change in expression levels of moisturizing-related markers (filaggrin, hyaluronan synthase) following the administration of the Lacticase Bacillus paracasei subspecies paracasei (Lc.paracasei) ABF21013 strain.

[0195] Meanwhile, the HA content measured in the dermis isolated from the skin tissue of mice irradiated with UV rays was 70.4±16.42 ng / ㎖, which was significantly reduced compared to the Untreated group, where 115.8±21.93 ng / ㎖ was measured (**p<0.01). In addition, HA was detected at 116.2±21.63 ng / ㎖ (##p<0.01) in the UV+ABF21013LD group and 171.0±38.83 ng / ㎖ (####p<0.0001) in the UV+ABF21013HD group, both showing a significant increase compared to UV only (Fig. 9). Fig. 9 shows the results of confirming the change in hyaluronic acid expression levels following the administration of the Lacticase Bacillus paracasei subspecies paracasei (Lc. paracasei) ABF21013 strain.

[0196]

Claims

1. Lacticaseibacillus paracasei subspecies paracasei ABF21013 strain (Deposit No.: KCTC 16093BP).

2. A food composition for preventing or improving photoaging comprising the strain Lacticaseibacillus paracaseisubsp. paracasei ABF21013 (Deposit No.: KCTC 16093BP).

3. In Paragraph 2, The above strain is, A food composition comprising one or more combinations selected from the live cells of the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain, the lysate thereof, the culture solution thereof, the culture solution thereof, the concentrate thereof, the dried product thereof, the extract thereof, the extract solution thereof, and the dead cells thereof.

4. In Paragraph 2, The above photoaging is, A food composition that is induced by ultraviolet irradiation.

5. A food composition for improving wrinkles or promoting skin elasticity comprising the strain Lacticaseibacillus paracaseisubsp. paracasei ABF21013 (Deposit No.: KCTC 16093BP).

6. A moisturizing food composition comprising the strain Lacticaseibacillus paracaseis subsp. paracasei ABF21013 (Deposit No.: KCTC 16093BP).

7. A cosmetic composition for preventing or improving photoaging comprising the strain Lacticaseibacillus paracaseis subsp. paracasei ABF21013 (Deposit No.: KCTC 16093BP).

8. In Paragraph 7, The above strain is, A cosmetic composition comprising one or more combinations selected from the live cells of the Lacticaseibacillus paracaseis subsp. paracasei ABF21013 strain, the lysate thereof, the culture solution thereof, the culture solution thereof, the concentrate thereof, the dried product thereof, the extract thereof, the extract solution thereof, and the dead cells thereof.

9. In Paragraph 7, The above photoaging is, A cosmetic composition that is induced by ultraviolet irradiation.

10. A cosmetic composition for improving wrinkles or enhancing skin elasticity comprising the strain Lacticaseibacillus paracaseis subsp. paracasei ABF21013 (Deposit No.: KCTC 16093BP).

11. A moisturizing cosmetic composition comprising the strain Lacticaseibacillus paracaseis subsp. paracasei ABF21013 (Deposit No.: KCTC 16093BP).

Images